Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 1/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 13/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.34 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.34 |
| ▸ | TOP2A | P11388 | 2/20 | 0.33 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20549414 | 0.88 | SCN5A (0.70) | SCN5AKCNH2LMNACYP3A4PIM1 | |
| SCHEMBL20549509 | 0.88 | KCNH2 (0.55) | SCN5AKCNH2LMNACYP3A4 | |
| Trifluoroacetic Acid SCHEMBL20549519 | 0.86 | KCNH2 (0.68) | SCN5AKCNH2TOP2ATOP2B | |
| SCHEMBL20549954 | 0.83 | SCN5A (0.67) | SCN5AKCNH2TOP2ATOP2B | |
| SCHEMBL20549945 | 0.82 | KCNH2 (0.73) | SCN5AKCNH2TOP2ATOP2B | |
| SCHEMBL20549576 | 0.82 | KCNH2 (0.73) | SCN5AKCNH2TOP2ATOP2B | |
| SCHEMBL20549586 | 0.82 | KCNH2 (0.73) | SCN5AKCNH2TOP2ATOP2B | |
| Hydrochloric Acid SCHEMBL20549549 | 0.81 | KCNH2 (0.72) | SCN5AKCNH2TOP2ATOP2B | |
| Hydrochloric Acid SCHEMBL20549561 | 0.81 | SCN5A (0.67) | SCN5AKCNH2LMNACYP3A4PIM1 | |
| Hydrochloric Acid SCHEMBL20549429 | 0.81 | SCN5A (0.67) | SCN5AKCNH2CYP3A4PIM1GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180318311-A1 | TRICYCLIC 2-QUINOLINONES AS ANTIBACTERIALS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2018-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180318311-A1 | TRICYCLIC 2-QUINOLINONES AS ANTIBACTERIALS | TOP1, TOP2A, TOP2B | SCN5A 1467/4885KCNH2 2920/4885LMNA 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.